Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease | Circul...
Background: In FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk), the proprotein convertase subtilisin-kexin type 9 inhibitor evolocumab reduced...